Skip to Content
Top

BY Ron Gilmore

A genome-wide association study has tied common genetic variants to pre-treatment pain, a finding with potential implications for precision medicine-based therapy decisions for patients with squamous cell carcinoma of the head and neck (HNSCC).Study findings were published in the Sept. 27 issue of Nature's Scientific Reports. The investigation was led by a multidisciplinary team including principal investigator Cielito Reyes-Gibby...

BY Ron Gilmore

A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for stopping the disease...

BY Laura Sussman

Mastectomy plus reconstruction for patients with early-stage breast cancer is significantly riskier and costlier than other less-invasive...

BY Scott Merville

In a pilot study of 13 newly diagnosed, BRCA-positive breast cancer patients at MD Anderson, all had their tumors shrink significantly when treated with the drug talazoparib before presurgical chemotherapy.

Tumor shrinkage after two months of treatment with the drug, measured by ultrasound, ranged from 30 to 98%, with an average reduction in tumor volume of 78% among the 13 patients.

“Acknowledging that this is a small study...

PARP inhibitors BRCA-positive breast cancer

BY Scott Merville

“Loss of interferon-gamma signaling caused by these mutations is the first clearly defined resistance pathway to ipilimumab found in tumor...